134 related articles for article (PubMed ID: 38503591)
21. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
22. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities.
Ito M; Yoshioka Y; Takase Y; Suzuki J; Matsunaga T; Takahashi H; Takeuchi A; Adachi S; Abe S; Oshima Y; Ohtakara K; Suzuki K; Okuda T
Jpn J Clin Oncol; 2021 Aug; 51(8):1253-1260. PubMed ID: 34128053
[TBL] [Abstract][Full Text] [Related]
24. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.
Sandhu AS; Zelefsky MJ; Lee HJ; Lombardi D; Fuks Z; Leibel SA
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):643-7. PubMed ID: 11020559
[TBL] [Abstract][Full Text] [Related]
25. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
26. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
27. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
Budäus L; Bolla M; Bossi A; Cozzarini C; Crook J; Widmark A; Wiegel T
Eur Urol; 2012 Jan; 61(1):112-27. PubMed ID: 22001105
[TBL] [Abstract][Full Text] [Related]
28. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
29. Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer.
McGee L; Mendenhall NP; Henderson RH; Morris CG; Nichols RC; Marcus RJ; Li Z; Mendenhall WM; Williams CR; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):470-6. PubMed ID: 23244673
[TBL] [Abstract][Full Text] [Related]
30. Predicting post-radiation genitourinary hospital admissions in patients with localised prostate cancer.
David R; Hiwase M; Kahokehr AA; Lee J; Watson DI; Leung J; O'Callaghan ME
World J Urol; 2022 Dec; 40(12):2911-2918. PubMed ID: 36357601
[TBL] [Abstract][Full Text] [Related]
31. Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.
McDonald AM; Baker CB; Popple RA; Shekar K; Yang ES; Jacob R; Cardan R; Kim RY; Fiveash JB
Radiat Oncol; 2014 Jun; 9():129. PubMed ID: 24893842
[TBL] [Abstract][Full Text] [Related]
32. Anatomy-based inverse optimization in high-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: comparison of incidence of acute genitourinary toxicity between anatomy-based inverse optimization and geometric optimization.
Akimoto T; Katoh H; Kitamoto Y; Shirai K; Shioya M; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1360-6. PubMed ID: 16406395
[TBL] [Abstract][Full Text] [Related]
33. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
[TBL] [Abstract][Full Text] [Related]
34. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):81-8. PubMed ID: 14697424
[TBL] [Abstract][Full Text] [Related]
35. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
[TBL] [Abstract][Full Text] [Related]
36. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
[TBL] [Abstract][Full Text] [Related]
37. Energy delivery systems for treatment of benign prostatic hyperplasia: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(17):1-121. PubMed ID: 23074487
[TBL] [Abstract][Full Text] [Related]
38. Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy.
Byrne K; Hruby G; Kneebone A; Whalley D; Guo L; McCloud P; Eade T
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):617-625. PubMed ID: 28416260
[TBL] [Abstract][Full Text] [Related]
39. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
[TBL] [Abstract][Full Text] [Related]
40. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):648-53. PubMed ID: 15380602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
